Shares of SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) have earned a consensus rating of “Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. Five equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have updated their coverage on the stock […]
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the stock, Marketbeat reports. Five analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is […]
SI-BONE, Inc. (NASDAQ:SIBN – Get Rating) has been assigned an average recommendation of “Buy” from the eight analysts that are presently covering the firm, MarketBeat.com reports. Seven research analysts have rated the stock with a buy rating. The average 12-month price target among analysts that have issued ratings on the stock in the last year […]
SI-BONE (NASDAQ:SIBN – Get Rating)‘s stock had its “buy” rating restated by stock analysts at JMP Securities in a research report issued on Wednesday, TipRanks reports. They presently have a $36.00 price target on the stock. JMP Securities’ price objective suggests a potential upside of 149.13% from the company’s previous close. SIBN has been the […]
Zacks Investment Research upgraded shares of SI-BONE (NASDAQ:SIBN – Get Rating) from a sell rating to a hold rating in a research report sent to investors on Friday, Zacks.com reports. According to Zacks, “SI-BONE Inc. is a medical device company which developed the iFuse Implant System(R) for minimally invasive surgical treatment of the sacroiliac joint […]